COVID-19 Impact Assessment on Influenza Vaccines Market : Facts, Figures and Analytical Insights 2020-2026

The Global Influenza Vaccines Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Worldwide Influenza Vaccines Market size is expected to exceed USD 7.5 billion by 2027.
The report contains a deep analysis of the worldwide influenza vaccines market with size in terms of both value and volume. The report provides a clear insight into current and future developments of the worldwide influenza vaccines market. The report also explores a detailed analysis of the children and adults vaccinated with influenza vaccines worldwide from 2013 to 2019 and forecasts to 2027. It provides essential insights into influenza vaccines market revenue for the top 21 regional and national, and forecast until 2027.

Get Sample Report:
https://www.marketinsightsreports.com/reports/04272008336/worldwide-influenza-vaccines-market-size-share-analysis-growth-trends-and-forecast-to-2027/inquiry?source=openpr&Mode=12

Top Leading Companies of Global Influenza Vaccines Market are Sanofi Pasteur, GlaxoSmithKline (GSK), Seqirus (CSL Limited), AstraZeneca, Mylan, Gamma Vaccines Pty Ltd., Hualan Biological Engineering Inc., Shanghai Institute of Biological Products Co., Ltd., BioDiem, Novavax, BiondVax Pharmaceuticals Ltd., Medicago, Moderna Inc, Pneumagen, Daiichi Sankyo, Altimmune, FluGen, Imutex and others.

26 July 2020 bridgewater: Sanofi begins shipment of influenza vaccine doses in US

Sanofi Pasteur, the vaccines global business unit of Sanofi, has shipped the first of its influenza vaccine doses to health care providers in the U.S. to help protect Americans of all ages for the upcoming 2020-2021 flu season. Shipments will continue through the beginning of November in alignment with customer requests and in time for the start of vaccination efforts.As per its recent release, to respond to the expected increased demand, the company has increased its influenza vaccines production and market distribution compared to last year.

15 July 2019 -- GSK today announced it will begin shipping its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2019-20 flu season, immediately following licensing and lot-release approval from the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research. “CDC recommends that everyone 6 months of age and older get a flu shot every season,” said Judy Stewart, Senior Vice President, US Vaccines. “To simplify vaccine storage and procurement and to help healthcare professionals realize every appropriate vaccination opportunity, GSK offers two influenza vaccines with the same vaccine dose for all recommended patients.”

GSK expects to supply more than 40 million total doses of its influenza vaccines for the US market in the 2019-20 season. FLULAVAL QUADRIVALENT will be available in a 5mL, multidose vial containing 10 doses (0.5mL each) and a 0.5mL, single-dose, prefilled syringe. FLUARIX QUADRIVALENT will be available in a 0.5mL, single-dose, prefilled syringe.

30 Jul 2020: Seqirus, a global leader in influenza prevention, announced today it has begun shipping its portfolio of seasonal influenza vaccines to customers in the U.S. for the 2020/21 influenza season. Seqirus is one of the world’s largest influenza vaccine companies and is well-positioned to supply up to 60 million doses* for the U.S. market this year, depending on demand.

“We are collaborating with our partners across the industry to ensure a reliable supply of influenza vaccines throughout the season to help as many eligible people as possible get an influenza vaccination,” said Dave Ross, Vice President, North America Commercial Operations at Seqirus. “Our healthcare system is facing an unprecedented public health crisis with COVID-19, and we are proud to provide healthcare providers and their patients with a broad range of influenza vaccine options as early as possible to help protect against influenza and help lessen the overall burden on our healthcare system.”

Seqirus has a broad portfolio of differentiated products for individuals six months of age to adults 65 years and older, presented in pre-filled syringes as well as multi-dose vials.

The Report Analyses the Market Based on Countries and Presents the Forecast in Terms of Value and Volume for the Next Seven Years. Countries Covered in the Report Include: United States, Canada, Brazil, Germany, France, Italy, Spain, United Kingdom, Netherlands, Sweden, Denmark, Poland, Norway, Finland, Ireland, Belgium, Australia, New Zealand, Japan, China, India

Buy This Report:
https://www.marketinsightsreports.com/report/purchase/04272008336?mode=su?source=openpr&Mode=12

Following are major Table of Content of Global Influenza Vaccines Industry:

• Global Influenza Vaccines Market Sales Overview.
• Global Influenza Vaccines Market Sales Competition by Manufacturers.
• Global Influenza Vaccines Market Sales Analysis by Region.
• Global Influenza Vaccines Market Sales Analysis by Type.
• Global Influenza Vaccines Market Analysis by Application.
• Global Influenza Vaccines Market -Manufacturers Analysis.

Furthermore, this study will help our clients solve the following issues:

Cyclical dynamics - We foresee dynamics of industries by using core analytical and unconventional market research approaches. Our clients use insights provided by us to maneuver themselves through market uncertainties and interferences.

Identifying key cannibalizes - Strong substitute of a product or service is the most important threat. Our clients can identify key cannibalizes of a market, by procuring our research. This helps them in aligning their new product development/launch strategies in advance.

Spotting emerging trends – The report help clients to spot upcoming hot market trends. We also track possible impact and disruptions which a market would witness by a particular emerging trend. Our proactive analysis help clients to have early mover advantage.

Interrelated opportunities - This report will allow clients to make decisions based on data, thereby increasing the chances that the strategies will perform better if not best in real world.

We Offer Customization on report based on specific client Requirement:

– Free country Level analysis for any 5 countries of your choice.
– Free Competitive analysis of any 5 key market players.
– Free 40 analyst hours to cover any other data point.

Browse Full Report at:
https://www.marketinsightsreports.com/reports/04272008336/worldwide-influenza-vaccines-market-size-share-analysis-growth-trends-and-forecast-to-2027?source=openpr&Mode=12

Note: All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

Contact Us:
Irfan Tamboli (Head of Sales) – Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
sales@marketinsightsreports.com | irfan@marketinsightsreports.com

About Us:
MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides Global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

This release was published on openPR.